Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
08 janv. 2023 19h00 HE
|
Esperion Therapeutics, Inc.
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive...
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
17 oct. 2022 08h02 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04 août 2022 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new...
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
02 août 2022 07h00 HE
|
Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
01 nov. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of...
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
22 juin 2020 07h00 HE
|
Esperion Therapeutics, Inc.
Esperion to Receive $150 Million Milestone Payment in June Esperion Completes Transfer of Marketing Authorization Approvals (MAAs) for NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and...
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
14 juin 2020 09h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American...
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
08 juin 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
27 mai 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
15 mai 2020 18h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion’s Board of Directors granted 88,902...